STOCK TITAN

Enveric Biosciences, Inc. - ENVB STOCK NEWS

Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.

Enveric Biosciences, Inc. (ENVB) is a pioneering biotechnology company committed to the development of innovative neuroplastogenic small-molecule therapeutics aimed at treating mental health conditions such as depression, anxiety, and addiction disorders. Headquartered in the United States, Enveric is at the forefront of mental health research, with a focus on non-hallucinogenic solutions.

The company's flagship program, EB-003, represents a novel approach to tackling challenging mental health disorders. Unlike traditional treatments, EB-003 promotes neuroplasticity without causing hallucinations, providing a safer and potentially more effective option for patients.

Another key project in Enveric's pipeline is EB-002, previously known as EB-373. This next-generation synthetic prodrug of psilocin is being developed to offer new hope in the treatment of psychiatric disorders. With an emphasis on rigorous scientific research and clinical trials, Enveric strives to deliver breakthrough therapies that can significantly improve patients' quality of life.

Enveric's strategic vision includes forming partnerships and collaborations to enhance its research capabilities and accelerate the development of its therapeutic programs. Highlighting its commitment to innovation, the company is also investing in cutting-edge technologies such as artificial intelligence (AI) to further its research and development efforts.

Financially, Enveric Biosciences has been transparent about its funding efforts, ensuring that it maintains a robust financial foundation to support its research initiatives. With a strong commitment to ethical practices and patient-centric solutions, Enveric is emerging as a key player in the biotech sector, focused on addressing some of the most pressing mental health challenges of our time.

Rhea-AI Summary
Enveric Biosciences receives U.S. patent for EVM301 Series of drug candidates targeting mental health disorders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences announces advances in screening for neuroplastogen drug candidates for mental health disorders. Poster presentation at ICMBB 2023 highlights screening protocol and potential therapeutic benefits. Research team generates strong experimental evidence for reduced hallucinogenic effect and promising effects in animal models of depression and anxiety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
conferences
-
Rhea-AI Summary
Enveric Biosciences files provisional patent application for AI-backed computational methods to identify tryptamine derived new chemical entities (NCEs) and model interaction with the 5-HT2A receptor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.66%
Tags
AI
Rhea-AI Summary
Enveric Biosciences receives new patent for tryptamine-derived prodrugs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences CEO to present at H.C. Wainwright Global Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences
-
Rhea-AI Summary
Enveric Biosciences receives U.S. patent for psilocin prodrug EB-373, enhancing intellectual property rights
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
none
Rhea-AI Summary
Enveric Biosciences completes manufacturing of drug material for EB-373, enabling preclinical work and human trials initiation. High purity of manufactured product allows for efficient handling and shipping without restrictions on controlled substances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.44%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
-
Rhea-AI Summary
Enveric Biosciences announces successful completion of preclinical ADME and toxicology studies for its lead candidate EB-373
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
none

FAQ

What is the current stock price of Enveric Biosciences (ENVB)?

The current stock price of Enveric Biosciences (ENVB) is $0.325 as of December 20, 2024.

What is the market cap of Enveric Biosciences (ENVB)?

The market cap of Enveric Biosciences (ENVB) is approximately 3.3M.

What does Enveric Biosciences specialize in?

Enveric Biosciences specializes in developing neuroplastogenic small-molecule therapeutics for treating depression, anxiety, and addiction disorders.

What is EB-003?

EB-003 is Enveric's lead program designed to promote neuroplasticity in treating mental health disorders without inducing hallucinations.

What is EB-002?

EB-002, formerly known as EB-373, is a next-generation synthetic prodrug of psilocin being developed for the treatment of psychiatric disorders.

Where is Enveric Biosciences headquartered?

Enveric Biosciences is headquartered in the United States.

How does Enveric Biosciences fund its research?

Enveric Biosciences maintains a robust financial foundation through transparent funding efforts to support its research initiatives.

Is Enveric involved in any partnerships or collaborations?

Yes, Enveric forms strategic partnerships and collaborations to enhance its research capabilities and accelerate its therapeutic programs.

How does Enveric ensure its treatments do not cause hallucinations?

Enveric focuses on non-hallucinogenic solutions, as evidenced by its lead program, EB-003, which promotes neuroplasticity without causing hallucinations.

What technologies is Enveric investing in?

Enveric is investing in cutting-edge technologies such as artificial intelligence (AI) to advance its research and development efforts.

What are the core values of Enveric Biosciences?

Enveric Biosciences is committed to ethical practices, patient-centric solutions, and innovative research to address mental health challenges.

Why is Enveric considered a key player in the biotech sector?

Enveric is emerging as a key player due to its pioneering approaches to mental health treatments and significant investments in innovative research.

Enveric Biosciences, Inc.

Nasdaq:ENVB

ENVB Rankings

ENVB Stock Data

3.32M
9.59M
6.93%
7.06%
3.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NAPLES